Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $674.3 million.

  • Neurocrine Biosciences' Accounts Payables rose 4607.89% to $674.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $674.3 million, marking a year-over-year increase of 4607.89%. This contributed to the annual value of $674.3 million for FY2025, which is 4607.89% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Accounts Payables is $674.3 million, which was up 4607.89% from $584.3 million recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Accounts Payables high stood at $674.3 million for Q4 2025, and its period low was $171.9 million during Q1 2021.
  • Its 4-year average for Accounts Payables is $408.1 million, with a median of $417.2 million in 2024.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 2192.84% in 2024, then skyrocketed by 4879.04% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Accounts Payables (Quarter) stood at $205.9 million in 2021, then surged by 117.97% to $448.8 million in 2023, then increased by 2.85% to $461.6 million in 2024, then skyrocketed by 46.08% to $674.3 million in 2025.
  • Its Accounts Payables was $674.3 million in Q4 2025, compared to $584.3 million in Q3 2025 and $489.5 million in Q2 2025.